🇺🇸 FDA
Patent

US 11149321

Methods and compositions for targeted single-stranded cleavage and targeted integration

granted A61KA61K38/00A61P

Quick answer

US patent 11149321 (Methods and compositions for targeted single-stranded cleavage and targeted integration) held by Sangamo Therapeutics, Inc. expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61P, A61P31/12, A61P43/00